Composur, a Patient-centric, Phase IV, Open-label, Prospective, Real World US Study to Evaluate Vibegron on Patient Treatment Satisfaction, Quality of Life, and Healthcare Resource Utilization in Overactive Bladder
Latest Information Update: 07 May 2025
At a glance
- Drugs Vibegron (Primary)
- Indications Overactive bladder
- Focus Therapeutic Use
- Acronyms Composur
- Sponsors Sumitomo Pharma America; Urovant Sciences
Most Recent Events
- 07 May 2025 According to a Sumitomo Pharma media release, data from this study presented at the 2025 American Urological Association Annual Meeting.
- 29 Apr 2025 Results presented in the Sumitomo Pharma Media Release.
- 27 Dec 2024 Status changed from active, no longer recruiting to completed.